Novel docetaxel-loaded nanoparticles based on PCL-Tween 80 copolymer for cancer treatment
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The formulation of docetaxel available for clinical use (Taxotere) contains a high concentration of polysorbate 80 (Tween 80). After incorporation of Tween 80 into poly-ɛ-caprolactone (PCL)-Tween 80 copolymer, the relative amount of Tween 80 should be decreased and the advantages of PCL and Tween 80 should be combined. METHODS: A novel PCL-Tween 80 copolymer was synthesized from ɛ-caprolactone and Tween 80 in the presence of stannous octoate as a catalyst via ring opening polymerization. Two types of nanoparticle formulation were made from commercial PCL and a self-synthesized PCL-Tween 80 copolymer using a modified solvent extraction/evaporation method. RESULTS: The nanoparticles were found by field emission scanning electron microscopy to have a spherical shape and be 200 nm in diameter. The copolymers could encapsulate 10% of the drug in the nanoparticles and release 34.9% of the encapsulated drug over 28 days. PCL-Tween 80 nanoparticles could be internalized into the cells and had higher cellular uptake than the PCL nanoparticles. The drug-loaded PCL-Tween 80 nanoparticles showed better in vitro cytotoxicity towards C6 cancer cells than commercial Taxotere at the same drug concentration. CONCLUSION: Nanoparticles using PCL-Tween 80 copolymer as drug delivery vehicles may have a promising outcome for cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107
FTIR study of polycaprolactone chain organization at interfaces
Elzein, T., Nasser-Eddine, M., Delaite, C., Bistac, S., & Dumas, P. (2004) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2004.02.001 · Cited by 814
Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., & Alyautdin, R. (2002) · Journal of drug targeting · doi:10.1080/10611860290031877 · Cited by 801 · cited 1×
“11 12–15 It was reported that Tween 80-coated polybutylcyanoacrylate nanoparticles could enhance brain concentrations of administered doxorubicin by about 60-fold in mice.”
Long-circulating pegylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery.
Calvo, P., Gouritin, B., Chacun, H., Desmaële, D., D'Angelo, J., Noel, J.-P., Georgin, D., Fattal, E., Andreux, J. P., & Couvreur, P. (2001) · Pharmaceutical Research · doi:10.1023/a:1010931127745 · Cited by 443
Nanoparticle uptake by the oral route: Fulfilling its potential?
Florence, A. T. (2005) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2005.05.019 · Cited by 248
Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles
Panagi, Z., Beletsi, A., Evangelatos, G., Livaniou, E., Ithakissios, D. S., & Avgoustakis, K. (2001) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00676-7 · Cited by 215 · cited 1×
“However, nanoparticles can be rapidly eliminated/excreted by macrophages in the reticuloendothelial system located primarily in the liver and spleen, resulting in a short half-life in the circulation after intravenous administration.(1) Various attempts have been made to achieve a longer circulation time to avoid or r…”
Cited by
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Dhand, C., Dwivedi, N., Loh, X. J., Jie Ying, A. N., Verma, N. K., Beuerman, R. W., Lakshminarayanan, R., & Ramakrishna, S. (2015) · RSC Advances · doi:10.1039/c5ra19388e · Cited by 795
Moradi Kashkooli, F., Soltani, M., & Souri, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.012 · Cited by 514
Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges
Zhang, W., Mehta, A., Tong, Z., Esser, L., & Voelcker, N. H. (2021) · Advanced Science · doi:10.1002/advs.202003937 · Cited by 430
Key interactions of surfactants in therapeutic protein formulations: A review
Khan, T. A., Mahler, H.-C., & Kishore, R. S. K. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.09.016 · Cited by 287
Zeng, X., Tao, W., Mei, L., Huang, L., Tan, C., & Feng, S.-S. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.052 · Cited by 282
Self-citationNanocarrier for Poorly Water-Soluble Anticancer Drugs—Barriers of Translation and Solutions
Narvekar, M., Xue, H. Y., Eoh, J. Y., & Wong, H. L. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0107-x · Cited by 257
Towards principled design of cancer nanomedicine to accelerate clinical translation
Souri, M., Soltani, M., Moradi Kashkooli, F., Kiani Shahvandi, M., Chiani, M., Shariati, F. S., Mehrabi, M. R., & Munn, L. L. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100208 · Cited by 159
El-Zaafarany, G. M., Soliman, M. E., Mansour, S., & Awad, G. A. S. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.02.038 · Cited by 89
Metadata
- Authors
- Mei, L., Zeng, Cheng, Zheng, Song, Huang, & Ma
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2011-11
- Volume
- 6
- Pages
- 2679
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W2110076300
- Cited by
- 89
- References
- 7
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.